In addition to Wuhan pneumonia, vaccines for other diseases are actually under active development. Among them, after years of development, the malaria vaccine finally has the first approved by the WHO, which is expected to increase the survival rate of children in Africa.
The vaccine approved by the WHO this time is Mosquirix developed by GSK (GlaxoSmithKline), which was launched in 1987 and was approved by the European Union in 2015. This vaccine requires 4 doses to be effective.
The protection rate against severe childhood illness is 32%, which is far lower than the 90% protection rate of measles or varicella vaccine. The WHO recommends that all children in Africa receive this vaccine.
Even so, Mosquirix itself has low cost and safety characteristics, and it can still bring significant help to Africa with serious malaria problems.
WHO estimates that more than 260,000 children die from malaria in Africa each year, and 400,000 people die from malaria each year globally.
GSK stated that they can provide 15 million doses of Mosquirix vaccine each year at a cost plus no more than 5%. In addition, the malaria vaccine R21, which is currently developed based on mRNA technology, is also being developed at the University of Oxford, with an effective rate of 77% currently tested.
WHO Approved The First Malaria Vaccine Developed As Early As The 1980s With Low Cost And Safety Features
10/09/2021 12:44:00 pm
0

Be Civil, No Spam!!!